US FDA: Pharmaceutical Distribution Entering DSCSA Compliance ‘Stabilization Period’
Executive Summary
Agency officials advise drug supply chain partners what stabilization activities they expect to see during one-year “enforcement discretion” period; industry lawyers advise that anyone found coasting could face discretionary enforcement. More discretion, more guidance in the works, including a final ruling on state preemption.
You may also be interested in...
As Supply Chain Partners Ramp Up For November DSCSA Deadline, US FDA Gives Them Another Year
Potential distribution hitches could spark shortages of legitimate drugs if the system is not fully ready for package-level tracing requirements, US FDA says in delaying enforcement of the program a decade in the making. Poll shows supply chain partners were making significant progress in preparing for the 27 November deadline.
The Quality Lowdown: As Washington Churns On Drug Shortages, Supply Chain Challenges Grow
While FDA commissioner meets with firms on shortages, senators challenge alternative source of platinum chemotherapies, FDA hinges imports from Sun plant on successful media fill runs, Safe Chain warned on Biktarvy suppliers, and the FDA asks Ipca more questions while setting “Mr. Ye” straight.
US FDA’s Drug Distributor Licensing Plan Preempts Potentially Stricter State Rules
National plan would close regulatory gaps in licensure of wholesalers and shipping companies, but also backs away from earlier idea to let states set stricter requirements.